Clinical Trial Update: Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update evaluating the combination of Samarium-153 lexidronam pentasodium and bortezomib in relapsed or refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Bortezomib (bortezomib)
• Quadramet (samarium-153 lexidronam pentasodium)

Snippet

Sponsor: Mayo Clinic | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 1, Phase 2 | Status: COMPLETED